Nanobiotix

Nanobiotix is one of the...

• CAC All-Trade.

Nanobiotix is a company listed under the stock ticker NANO (FR).

View the org chart displaying its 18 main executives

Most searched biographies at Nanobiotix

• Laurent Levy, Chief Executive Officer
• Alain Herrera, Director
• Enno Spillner, Director

Popular executive movements at Nanobiotix

• Louis Kayitalire has joined the company as Chief Medical Officer  (posted on September 6 2023).

Create your alert
to follow the executive moves at Nanobiotix.

Nanobiotix has 2,281 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
• Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
• Histogen has filed for bankruptcy protection  (posted on April 19 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Vik Bajaj - Director at Interline Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by Nanobiotix

• Press Releases | Nanobiotix
• Voting Rights and Shares Capital of the Company | Nanobiotix
• NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023 | Nanobiotix
• NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M
• NANOBIOTIX Announces Closing of Global Offering | Nanobiotix
• NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference | Nanobiotix
• NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer | Nanobiotix
• NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3 | Nanobiotix
• NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023 | Nanobiotix
• Voting Rights and Shares Capital of the Company | Nanobiotix S.A.
• View more press releases Close

Social media about Nanobiotix

• Nanobiotix on Wikipedia, Google News & Yahoo Finance
• Nanobiotix on LinkedIn, Twitter & YouTube

Contact by email its executives including Laurent Levy

Call Nanobiotix at +33 14...

View the org chart

Register to receive your alert

Report an error